A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 (Bronx)
|Male and Female Patients
|U.S. Govt. ID:
|Logan Posey: 347-590-7280 / firstname.lastname@example.org
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19. The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.
This study is closed
Jessica Justman, MD
|Are you 18 years old or older?
|Have you ever tested positive for Sars-Co-V-2 (Covid-19)?
|Are you currently pregnant? If N/A select No.
|Are you preventing pregnancy (i.e. birth control)? If N/A select Yes.
|Are you willing to travel to the South Bronx for participation in this study?